ETFs positioned on Ipsen

Name YTD change Weight AuM
+11.12% - 27,154 M€
+7.08% - 92 M€
+12.57% - 13 M€
+5.80% - 49 M€
+0.92% - 51 M€
+12.21% - 66 M€
+11.50% - 24,432 M€
+10.30% - 75 M€
+9.73% - 67 M€
+7.92% - 6 M€
+5.53% - 1,193 M€
+7.72% - 6,576 M€
+11.50% - 3,469 M€
+8.47% - 5,871 M€
0.00%4.67% 8 M€
+66.86%3.96% 215 M€
+17.70%3.25% 23 M€
+16.58%1.94% 31 M€
+8.58%1.94% 31 M€
+2.69%1.75% 574 M€
+12.24%1.54% 18 M€
+12.86%1.52% 17 M€
+11.80%1.48% 160 M€
0.00%1.05% 208 M€
0.00%1.05% 26 M€
+11.13%0.98% 125 M€
+10.52%0.87% 730 M€
+10.47%0.83% 55 M€
+10.27%0.83% 20 M€
+28.53%0.79% 1,260 M€
+14.23%0.78% 103 M€
+11.04%0.59% 140 M€
+1.14%0.58% 38 M€
+9.48%0.54% 51 M€
+10.47%0.53% 40 M€
+7.17%0.5% 23 M€
+10.87%0.47% 937 M€
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535